B2M and neoplasm: Due to the natural activity of NK cells against melanoma cells and their strong killing effect on tumor cells with reduced expression of MCH class I molecules, NK cell-based therapy is promising immunotherapy for ICI-resistant melanoma caused by β2M deficiency (83, 84).